Breaking News Instant updates and real-time market news.

GILD

Gilead

$73.27

-0.9 (-1.21%)

, GLPG

Galapagos NV

$107.66

2.29 (2.17%)

13:34
10/21/18
10/21
13:34
10/21/18
13:34

Gilead, Galapagos NV announced data from Phase 3 FINCH2 trial of filgotinib

Gilead Sciences (GILD) and Galapagos NV (GLPG) announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20%, 50% and 70% responses, low disease activity and clinical remission at Weeks 12 and 24. Additional FINCH 2 data to be presented include positive results across several patient-reported health-related quality of life measures. Patients receiving filgotinib 100mg or 200mg once-daily experienced greater reduction in the Health Assessment Questionnaire Disability Index at Week 12 compared with those receiving placebo. Patients receiving filgotinib 100mg or 200mg also experienced greater improvements on the Short-Form Health Survey Physical Component Score at Week 12 and on the Functional Assessment of Chronic Illness Therapy-Fatigue Scale at Week 12 compared with patients receiving placebo. Filgotinib demonstrated a safety profile consistent with earlier clinical trials. Rates of serious treatment-emergent adverse events were similar for the filgotinib 100mg, 200mg and placebo groups. The proportion of patients who discontinued study drug due to treatment-emergent adverse events was also similar across groups. Serious infections occurred at similar rates across the three study arms. A total of four cases of uncomplicated Herpes zoster occurred in the filgotinib arms, and one non-serious case of retinal vein occlusion was reported in the filgotinib 200 mg group. Two major adverse cardiovascular events were reported, one in the filgotinib 100mg group and one in the placebo group. No deaths occurred during the study.

GILD

Gilead

$73.27

-0.9 (-1.21%)

GLPG

Galapagos NV

$107.66

2.29 (2.17%)

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 07

    Nov

GILD Gilead
$73.27

-0.9 (-1.21%)

10/05/18
SBSH
10/05/18
NO CHANGE
SBSH
Gilead may need Dicerna after Arrowhead, J&J deal, says Citi
Given the partnership announced yesterday between Arrowhead Pharmaceuticals (ARWR) and Johnson & Johnson (JNJ), Gilead Sciences' (GILD) hepatitis B virus portfolio may need another component and Dicerna Pharmaceuticals (DRNA) "could be one of them," Citi analyst Robyn Karnauskas tells investors in a research note. The analyst believes large pharma and Gilead are "still missing a key piece to bring a curative therapy to market that can rapidly and effectively lower HBsAg." The Arrowhead deal makes it apparent that HBV portfolios may need a multi-target approach and validates the RNAi platform to target HBV, the analyst contends.
10/02/18
JEFF
10/02/18
NO CHANGE
Target $135
JEFF
Buy
Jefferies sees Intercept moving higher after 'mixed' Gilead data
Jefferies analyst Michael Yee views Gilead Sciences' (GILD) new six-month nonalcoholic steatohepatitis data as "mixed and undifferentiated." As such, he thinks shares of Intercept Pharmaceuticals (ICPT) probably continue to move higher. The stock is likely to retrace back up into year-end and the first half of 2019 as Street realizes Intercept's Phase III will be positive and de-risked, Yee tells investors in a research note. He says the company has had various competitor Farnesoid X receptor data in Phase I/II read out over the past year or and that these have ended up not too differentiated. This has removed some of the competitive overhang on Intercept, the analyst contends. Yee keeps a Buy rating on the shares with a $135 price target.
10/01/18
CANT
10/01/18
INITIATION
Target $87
CANT
Overweight
Gilead initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young started Gilead Sciences with an Overweight rating and $87 price target.
09/25/18
JEFF
09/25/18
INITIATION
Target $75.5
JEFF
Buy
Cambrex initiated with a Buy at Jefferies
Jefferies analyst David Windley started Cambrex (CBM) with a Buy rating and $75.50 price target. The analyst sees the company, as a leading manufacturer of small molecule active pharmaceutical ingredients, benefiting from increased API outsourcing. He adds that his Gilead (GILD) analysis, Cambrex's top customer, is "differentiated and positive."
GLPG Galapagos NV
$107.66

2.29 (2.17%)

10/11/18
JEFF
10/11/18
NO CHANGE
Target $210
JEFF
Buy
Jefferies sees shares of Vertex 'going back up and recovering'
Shares of Vertex Pharmaceuticals (VRTX) have pulled back from recent highs of $190-$195 down to $175 on "risk-off rotation" amid the broader market selloff, Jefferies analyst Michael Yee tells investors in a research note. However, nothing fundamental has happened and Vertex still has the "cleanest growth story in large biotech," Yee contends. The triple pill has confirmed Phase III pivotal data coming Q4 and upcoming competitor Galapagos NV (GLPG) data "probably will eventually disappoint," claims the analyst. He also views CTX001 coming off clinical hold as a "nice positive" and thinks the company's pipeline is likely to start garnering more focus over the next 6-12 months. Yee sees the stock "eventually going back up and recovering" and keeps a Buy rating on Vertex with a $210 price target.
09/13/18
JPMS
09/13/18
INITIATION
Target $140
JPMS
Overweight
Galapagos NV initiated with an Overweight at JPMorgan
JPMorgan analyst James Quigley started Galapagos NV (GLPG) with an Overweight rating and $140 price target. The company's key value driver is filgotinib, a selective JAK1 inhibitor which has shown potential best in class data in inflammatory diseases and is licensed to Gilead (GILD), Quigley tells investors in a research note. The analyst forecasts peak in market filgotinib sales of EUR 4.4B. Quigley also sees value in Galapagos' wholly owned GLPG1690, which he says could be the first drug to halt disease progression in idiopathic pulmonary fibrosis.
09/12/18
JPMS
09/12/18
INITIATION
JPMS
Overweight
Galapagos NV initiated with an Overweight at JPMorgan
09/12/18
NOMU
09/12/18
NO CHANGE
Target $124
NOMU
Buy
Galapagos data meets expectations 'and then some,' says Nomura Instinet
Nomura Instinet analyst Christopher Marai says Galapagos NV (GLPG) and Gilead's (GILD) positive top-line results from the Finch-2 study evaluating filgotinib in moderate-to-severe rheumatoid arthritis patients met his expectations "and then some." The anlayst keeps a Buy rating on Galapagos with a $124 price target.

TODAY'S FREE FLY STORIES

EEX

Emerald Expositions Events

$10.92

-0.63 (-5.45%)

17:02
11/19/18
11/19
17:02
11/19/18
17:02
Initiation
Emerald Expositions Events initiated  »

Emerald Expositions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTAS

Cintas

$179.63

-3.47 (-1.90%)

16:58
11/19/18
11/19
16:58
11/19/18
16:58
Initiation
Cintas initiated  »

Cintas initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARMK

Aramark

$35.81

-1.045 (-2.84%)

16:52
11/19/18
11/19
16:52
11/19/18
16:52
Initiation
Aramark initiated  »

Aramark initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADT

ADT Inc.

$7.68

-0.39 (-4.83%)

, AMZN

Amazon.com

$1,511.67

-81.92 (-5.14%)

16:48
11/19/18
11/19
16:48
11/19/18
16:48
Initiation
ADT Inc., Amazon.com initiated  »

ADT Inc. initiated with…

ADT

ADT Inc.

$7.68

-0.39 (-4.83%)

AMZN

Amazon.com

$1,511.67

-81.92 (-5.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 28

    Nov

  • 04

    Dec

NUAN

Nuance

$16.27

-0.61 (-3.61%)

16:48
11/19/18
11/19
16:48
11/19/18
16:48
Hot Stocks
Nuance trades higher after quarterly report, plans to spin off Nuance Auto »

Shares of Nuance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

ORPN

Bio Blast Pharma

$1.19

-0.02 (-1.65%)

16:48
11/19/18
11/19
16:48
11/19/18
16:48
Conference/Events
Bio Blast Pharma to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSTG

Pure Storage

$17.56

-1.56 (-8.16%)

16:48
11/19/18
11/19
16:48
11/19/18
16:48
Hot Stocks
Pure Storage up 6.4% after Q3 results beat estimates, FY19 guidance raised »

In after-hours trading,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 26

    Nov

ORPN

Bio Blast Pharma

$1.19

-0.02 (-1.65%)

16:45
11/19/18
11/19
16:45
11/19/18
16:45
Hot Stocks
Breaking Hot Stocks news story on Bio Blast Pharma »

Bio Blast Pharma trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADT

ADT Inc.

$7.68

-0.39 (-4.83%)

16:43
11/19/18
11/19
16:43
11/19/18
16:43
Initiation
ADT Inc. initiated  »

ADT Inc initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

ARMK

Aramark

$35.81

-1.045 (-2.84%)

16:42
11/19/18
11/19
16:42
11/19/18
16:42
Initiation
Aramark initiated  »

Aramark initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTAS

Cintas

$179.63

-3.47 (-1.90%)

16:41
11/19/18
11/19
16:41
11/19/18
16:41
Initiation
Cintas initiated  »

Cintas initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BECN

Beacon Roofing

$27.74

0.12 (0.43%)

16:40
11/19/18
11/19
16:40
11/19/18
16:40
Earnings
Beacon Roofing sees FY19 adjusted EPS $2.90-$3.35, consensus $3.79 »

Sees FY19 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 13

    Dec

SERV

ServiceMaster

$41.84

-0.58 (-1.37%)

16:40
11/19/18
11/19
16:40
11/19/18
16:40
Initiation
ServiceMaster initiated  »

ServiceMaster initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

EEX

Emerald Expositions Events

$10.92

-0.63 (-5.45%)

16:39
11/19/18
11/19
16:39
11/19/18
16:39
Initiation
Emerald Expositions Events initiated  »

Emerald Expositions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBIP

Prudential Bancorp

$17.32

-0.03 (-0.17%)

16:38
11/19/18
11/19
16:38
11/19/18
16:38
Hot Stocks
Prudential Bancorp announces third stock repurchase program for 900,000 shares »

Prudential Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

POST

Post Holdings

$91.74

-4.31 (-4.49%)

16:37
11/19/18
11/19
16:37
11/19/18
16:37
Syndicate
Post Holdings announces termination of convertible preferred stock offering »

Post Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FULT

Fulton Financial

$16.89

-0.06 (-0.35%)

16:36
11/19/18
11/19
16:36
11/19/18
16:36
Hot Stocks
Fulton Financial announces special cash dividend of four cents per share »

Fulton Financial …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFG

National Fuel

$53.79

0.755 (1.42%)

16:35
11/19/18
11/19
16:35
11/19/18
16:35
Hot Stocks
National Fuel CIO Wegrzyn to retire »

National Fuel Gas Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LB

L Brands

$34.53

-0.75 (-2.13%)

16:35
11/19/18
11/19
16:35
11/19/18
16:35
Hot Stocks
L Brands names John Mehas as CEO of Victoria's Secret Lingerie unit »

The company also…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

XOMA

Xoma

$14.22

-0.045 (-0.32%)

16:35
11/19/18
11/19
16:35
11/19/18
16:35
Syndicate
Xoma commences rights offering to raise approximately $20M »

XOMA announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DNLI

Denali Therapeutics

$18.18

-1.05 (-5.46%)

, SNY

Sanofi

$44.92

-0.19 (-0.42%)

16:34
11/19/18
11/19
16:34
11/19/18
16:34
Hot Stocks
Denali Therapeutics reports 'positive' results from Phase 1 DNL747 study »

Denali Therapeutics…

DNLI

Denali Therapeutics

$18.18

-1.05 (-5.46%)

SNY

Sanofi

$44.92

-0.19 (-0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 28

    Jan

  • 11

    Mar

  • 22

    Mar

  • 28

    Apr

LB

L Brands

$34.53

-0.75 (-2.13%)

16:34
11/19/18
11/19
16:34
11/19/18
16:34
Earnings
L Brands raises FY18 EPS view to $2.60-$2.80 from $2.45-$2.70, consensus $2.63 »

CEO Leslie Wexner states:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

PGNX

Progenics

$5.20

-0.16 (-2.99%)

16:34
11/19/18
11/19
16:34
11/19/18
16:34
Hot Stocks
Progenics announces presentation of updated data for Azedra »

Progenics Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

LB

L Brands

$34.53

-0.75 (-2.13%)

16:34
11/19/18
11/19
16:34
11/19/18
16:34
Earnings
Breaking Earnings news story on L Brands »

L Brands sees Q4 EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

HGV

Hilton Grand Vacations

$29.52

-0.09 (-0.30%)

16:33
11/19/18
11/19
16:33
11/19/18
16:33
Hot Stocks
Hilton Grand Vacations names Gordon Gurnik as COO »

Hilton Grand Vacations…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.